Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

f unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the sufficiency of Nile's available capital, timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are descr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
(Date:8/28/2014)... New York, NY (PRWEB) August 28, 2014 ... has renewed its long term partnership with PTI ... to provide clients with state of the art leak ... state of the art instruments currently available. As part ... a new High Voltage Leak Detection Instrument ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics ... in metabolic disorders, announced today that it has filed ... Securities and Exchange Commission (SEC) relating to the proposed ... The number of shares to be offered and the ... determined. Citigroup and Cowen and Company will ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. (Amex: ... a 160-patient Phase 2 study,of alagebrium in patients with ... A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic Heart ... the effect of six months,of oral treatment with 400mg ...
... Yields First Milestone, NEW YORK, May 13 ... pre-disease collection, processing and long-term,storage of adult stem cells ... been secured for a new stem cell collection center ... Smith, MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: ...
... May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... Phase 2 study of subcutaneously,administered LHRH antagonist ... (BPH", has been accepted for publication in ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed ... to be used for muscle regeneration research as well ... FSHD. , The research is published in the current ... There is no treatment for FSHD, which is thought ... muscular dystrophy. FSHD is an unusual genetic disorder because, ...
(Date:8/28/2014)... Ga. The support of peer groups and ... breastfeeding programs, according to recent University of Georgia ... in the Athens-Clarke County area determined that role ... outcomes of mothers of infants. , "Mothers who ... successful at breastfeeding," said study co-author Alex Anderson, ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2
... which they can pass on to humans. But now research ... Research says that pigs get HEV early enough to minimise ... worry about would occur if the infection rate in pigs ... chance pigs will pass on HEV to humans at slaughter. ...
... Dr Pep Canadell, from the Global Carbon Project and CSIRO ... that tropical deforestation releases 1.5 billion tonnes of carbon each ... accounts for nearly 20 per cent of carbon emissions due ... estimated 87 to 130 billion tonnes of carbon by 2100, ...
... grazing normally on algae in the rocky intertidal zone of ... by a parasite. But the better news is, according to ... might have more to eat if plenty of your neighbors ... of the National Academy of Sciences Early Edition ( http://www.pnas.org/papbyrecent.shtml ...
Cached Biology News:Confirmed -- deforestation plays critical climate change role 2Parasites' impact goes beyond host to affect ecosystem 2Parasites' impact goes beyond host to affect ecosystem 3
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
Biology Products: